Communiqués GSK plc

Actions

GSK

GB00BN7SWP63

Produits pharmaceutiques

Marché Fermé - London S.E. Autres places de cotation 17:35:09 22/04/2026			Varia. 5j.	Varia. 1 janv.
2 075,00 ^GBX	-0,34 %		-2,63 %	+13,73 %

21/04	L'armée américaine n'est plus tenue de se faire vacciner contre la grippe, selon Hegseth	RE
21/04	Vaccins COVID et nouvelles thérapies dans l'incertitude après la suspension du comité consultatif de Kennedy par la justice américaine	RE

Communiqués

12/04	GSK : presents positive data for B7-H4-targeted ADC in gynaecological cancers	PU
10/04	The Time to Talk about HIV is Now: ViiV Healthcare Launches "Still Here" PSA to Ignite Action Around HIV on National Youth HIV/AIDS Awareness Day	BU
09/04	GSK : Q1 2026 pre announcement aide memoire	PU
30/03	GSK plc - Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B	AQ
25/03	GSK : Articles of Association - Proposed Amendments	PU
25/03	GSK : Proxy Form 2026	PU
25/03	GSK : Notice of AGM 2026	PU
23/03	GSK : B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan	PU
17/03	Eastern District Of Pennsylvania Dismisses Putative Securities Class Action Against Pharmaceutical Company As Time-Barred	AQ
16/03	GSK's RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18-49 years at increased risk	AQ
13/03	GlaxoSmithKline Egypt profit rises 22.5% y/y to $4.07mn in 2025	AQ
13/03	GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk	BU
13/03	GSK : RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased risk	PU
10/03	GSK : tops Antimicrobial Resistance (AMR) Benchmark Report	PU
09/03	GSK : and Alfasigma announce agreement on worldwide rights for linerixibat	PU
05/03	GSK : Governance And Remuneration Report 2025	PU
05/03	GSK : Responsible Business Report 2025	PU
05/03	GSK : Cautionary statement 2025	PU
03/03	GSK : completes acquisition of RAPT Therapeutics	PU
27/02	GSK plc - Linerixibat accepted for priority review in China for cholestatic pruritus in patients with primary biliary cholangitis	AQ
26/02	GSK enters agreement to acquire 35Pharma Inc.	AQ
25/02	GSK : ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen	PU
25/02	GSK : ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing	PU
23/02	Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract	BU
18/02	GSK : ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM	PU